Description
Indication & Scope
ReiMing® (Ruzinurad Sodium) contains ruzinurad sodium, a highly selective urate transporter 1 (URAT1) inhibitor for the treatment of hyperuricemia associated with gout.
- Mechanism: Selectively inhibits URAT1-mediated uric acid reabsorption in the renal proximal tubule, promoting uric acid excretion and reducing serum uric acid levels.
- Drug class: Highly selective urate transporter 1 (URAT1) inhibitor.
- Clinical use: Treatment of hyperuricemia associated with gout.
| Generic Name | Ruzinurad Sodium |
| Brand Name | ReiMing® |
| Ingredient | Each tablet contains ruzinurad sodium. |
| Dosage Form | Tablet |
| Package | 2.5 mg × 10 tablets/blister × 6 blisters/box |
| Conditions Treated | Treatment of hyperuricemia associated with gout. |
| Taboos | Hypersensitivity to ruzinurad sodium or any component of the product. |
| Place of origin | China |
| Prescription type | Prescription Drug (Rx) |
| Storage Conditions | Refer to the approved package labeling. |
| Manufacturer | Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
| Registration Authority | National Medical Products Administration (NMPA), China |
| Approval number | SHR4640 |
| Date of Revision | 2026 |
| Shelf Life | Refer to the approved package labeling |
How to use ?
Recommended Dose: The recommended starting dose is 1 mg once daily. After 1 week, the dose may be increased to 2.5 mg once daily. After another week, the dose may be increased to 5 mg once daily. Serum uric acid levels should be monitored after 2 weeks. If the target serum uric acid level is achieved, the dose may be maintained at 5 mg once daily. If the target level is not achieved, the dose may be adjusted to 10 mg once daily according to the patient’s condition.
Time: Administer orally once daily according to the approved dosing regimen.
Instructions for use: Take orally with sufficient water during treatment. Dose adjustment should be performed according to serum uric acid levels and the patient’s clinical condition.
Interaction: Refer to the approved package labeling for information on drug interactions.
Side effects: Refer to the approved package labeling for detailed safety information.
Important Notice
This product should be administered only by qualified healthcare professionals in accordance with the approved prescribing information and local clinical guidelines. Dosage and administration may vary depending on patient condition, indication, and regional regulatory requirements.
Packaging & Shipping
Packaging
Original manufacturer’s packaging with secure export carton. Customized export packaging is available upon request.
Shipping Methods
Express Courier (EMS, DHL, FedEx, UPS), Air Freight, and Sea Freight. Cold-chain transportation is available for products requiring temperature-controlled logistics.
Export Support
Certificate of Analysis
GMP Certificate
Commercial Invoice
Packing List & CPP
Cold Chain Logistics
Customs Documentation
Scientific and regulatory sources
FAQ
How does Ruzinurad Sodium lower uric acid levels?
Ruzinurad Sodium selectively inhibits URAT1, a transporter responsible for uric acid reabsorption in the kidney, thereby increasing uric acid excretion and reducing blood uric acid levels.
How should I take ReiMing® (Ruzinurad Sodium)?
It should be taken orally once daily with sufficient water. The dose should be adjusted according to the approved dosing regimen and serum uric acid levels.
What is the recommended starting dose of Ruzinurad Sodium?
The recommended starting dose is 1 mg once daily. The dose may be gradually increased according to serum uric acid levels and patient condition.
What are the key advantages of Ruzinurad Sodium?
Ruzinurad Sodium is a highly selective URAT1 inhibitor designed to promote uric acid excretion and provide an innovative treatment option for patients with gout-associated hyperuricemia.
RuiMing® Ruzinurad Sodium | High-Selective URAT1 Inhibitor | DengYueRX
INN: Ruzinurad Sodium
Indications: Treatment of gout with hyperuricemia.
Dosage Form: Tablets
Strength: 1 mg, 2.5 mg
